Preemptive Analgesia for Hemorrhoidectomy

Sponsor
Russian Society of Colorectal Surgeons (Other)
Overall Status
Recruiting
CT.gov ID
NCT04361695
Collaborator
(none)
144
1
2
29.9
4.8

Study Details

Study Description

Brief Summary

Preemptive analgesia with the spinal anesthesia allows to decrease pain in hemorrhoidectomy postoperative period. The purpose of this study is to assess the effectiveness of the use of preemptive analgesia with spinal anesthesia to decrease postoperative pain and the amount of used analgesics including opioids.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Hemorrhoidectomy, as has being demonstrated to be an effective method of treatment for stage III-IV hemorrhoidal disease. However it is associated with intense postoperative pain that requires the use of multimodal analgesia. Inadequate pain control leads to the prolongation of admission, increasing the consumption of opioid analgesics, patients dissatisfaction with treatment.

According to international guidelines of pain management the target level of postoperative pain should be 3-4 or less Visual Analogue Score (VAS) points. The multimodal analgesia including Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), acetaminophen and local anaesthetics are used to reach this aim.

However, there are data on effectiveness of preemptive analgesia in anorectal surgery. Preemptive analgesia allows decreasing pain in postoperative period after hemorrhoidectomy.

Ketoprophenum is used as an preemptive analgetic agent 1 hour prior to procedure.

The aim of this prospective, randomized, double-blind study is to assess the effectiveness of the use of preemptive analgesia with Ketoprophenum 10 mg 2 hours before procedure per os with spinal anaesthesia to decrease postoperative pain and the amount of used analgesics.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
144 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Preemptive Analgesia for Hemorrhoidectomy
Actual Study Start Date :
Feb 27, 2020
Anticipated Primary Completion Date :
Feb 25, 2021
Anticipated Study Completion Date :
Aug 25, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Ketoprophenum

A tablet with 10 mg Ketoprophenum is taken per os 2 hours before surgery

Procedure: Hemorrhoidectomy
The patient receives spinal anaesthesia and is placed in lithotomy position. A complex of external and internal haemorrhoid or internal haemorrhoid only is excised with monopolar electrocautery or bipolar electrosurgery device. Haemorrhoid pedicle is tied with absorbable polyfilament suture. One, two or three nodes can be removed per a procedure.

Drug: Ketoprophenum
Ketoprophenum

Placebo Comparator: Placebo

A tablet containing starch is taken per os 2 hours before surgery

Procedure: Hemorrhoidectomy
The patient receives spinal anaesthesia and is placed in lithotomy position. A complex of external and internal haemorrhoid or internal haemorrhoid only is excised with monopolar electrocautery or bipolar electrosurgery device. Haemorrhoid pedicle is tied with absorbable polyfilament suture. One, two or three nodes can be removed per a procedure.

Drug: Placebo
Placebo

Outcome Measures

Primary Outcome Measures

  1. The frequency of opioid analgesics usage [0-7 days postoperatively]

    The frequency of opioid administration per day

Secondary Outcome Measures

  1. Severity of pain [6, 12 and 24 hours after the operation, then 2 times per day up to 7th postoperative day]

    The severity of the pain syndrome before defecation and after defecation reported by the patient according to Visual Analogue Score (VAS), where 0 - the minimum pain, 10 - the worst pain.

  2. Duration of other analgesics usage [0-7 days postoperatively]

    The duration in days of systemic and topical analgesics usage

  3. Frequency of other analgesics usage [0-7 days postoperatively]

    Times per day of systemic and topical analgesics usage

  4. Re-admission rate [30 days postoperatively]

    The rate of patients who were re-admitted due to refractory pain

  5. Overall quality of life [7th and 30th days postoperatively]

    Assessed with patient-reported questionnaire Short Form 36 (SF-36). A total score in each of 8 sections will be calculated and transformed into a 0-100 scale with a score of zero equivalent to maximum disability and a score of 100 equivalent to no disability

  6. Returning to work [30 days postoperatively]

    The period of time in days from the operation to returning to work

  7. The rate of early postoperative complications [0-30 days postoperatively]

    The rate of complications: bleeding, retention of urine, infectious complications in early postoperative period

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Written informed consent.

  2. Patients over 18 years.

  3. Symptomatic grade III-IV haemorrhoids.

  4. Planned surgery: Milligan-Morgan hemorrhoidectomy

Exclusion Criteria:
  1. Patient's refusal to participate in the study.

  2. Pregnancy.

  3. Contraindication or technical inability to perform subarachnoid anaesthesia.

  4. Decompensated somatic diseases

Contacts and Locations

Locations

Site City State Country Postal Code
1 Clinic of Colorectal and Minimally Invasive Surgery Moscow Russian Federation 119435

Sponsors and Collaborators

  • Russian Society of Colorectal Surgeons

Investigators

  • Principal Investigator: Petr Tsarkov, Professor, Russian Society of Colorectal Surgeons

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Russian Society of Colorectal Surgeons
ClinicalTrials.gov Identifier:
NCT04361695
Other Study ID Numbers:
  • 10
First Posted:
Apr 24, 2020
Last Update Posted:
Apr 24, 2020
Last Verified:
Apr 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Apr 24, 2020